In prostate cancer cells, for instance, normally low C/EBPα protein (but not mRNA) levels massively increased in the presence of GSK3 inhibitors, while the higher C/EBPβ levels remained unchanged, suggesting that C/EBPα protein stability may be affected by GSK3 [267]. This evidence concerns the gene CEBPA and prostate carcinoma.